SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Dell'Orto P)
 

Search: WFRF:(Dell'Orto P) > (2010-2014) > Overall survival be...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Oakman, CHospital Prato, Italy (author)

Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer-8-year results of the Breast International Group 02-98 phase III trial

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • Oxford University Press (OUP): Policy A1,2013
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:liu-93386
  • https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-93386URI
  • https://doi.org/10.1093/annonc/mds627DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding Agencies|sanofi-aventis||Associazione Italiana Ricerca Cancro (AIRC), Milan, Italy||National Health and Medical Research Council|100925351164|Sanofi||Roche||Novartis||
  • Background: In women with node-positive breast cancer, the Breast International Group (BIG) 02-98 tested the incorporation of docetaxel (Taxotere) into doxorubicin (Adriamycin)-based chemotherapy, and compared sequential and concurrent docetaxel. At 5 years, there was a trend for improved disease-free survival (DFS) with docetaxel. We present results at 8-year median follow-up and exploratory analyses within biologically defined subtypes. less thanbrgreater than less thanbrgreater thanMethods: Patients were randomly assigned to one of four treatments: (i) sequential control: doxorubicin (A) (75 mg/m(2)) x 4 -andgt; classical cyclophosphamide, methotrexate, 5-fluorouracil (CMF); (ii) concurrent control: doxorubicin, cyclophosphamide (AC)(60/600 mg/m(2)) x 4 -andgt; CMF; (iii) sequential docetaxel: A (75 mg/m(2)) x3 -andgt; docetaxel (T) (100 mg/m(2)) x3. CMF and (iv) concurrent docetaxel: AT(50/75 mg/m(2)) x 4 -andgt; CMF. The primary comparison evaluated docetaxel efficacy regardless of the schedule. Exploratory analyses were undertaken within biologically defined subtypes. less thanbrgreater than less thanbrgreater thanResults: Two thousand eight hundred and eighty-seven patients were enrolled. After 93.4 months of median follow-up, there were 916 DFS events. For the primary comparison, there was no significant improvement in DFS from docetaxel [hazard ratio (HR) = 0.91, 95% confidence interval (CI) = 0.80-1.05, P = 0.187]. In secondary comparisons, sequential docetaxel significantly improved DFS compared with sequential control (HR = 0.81, 95% CI = 0.67-0.99, P = 0.036), and significantly improved DFS (HR = 0.84, 95% CI = 0.72-0.99, P = 0.035) and overall survival (OS) (HR = 0.79, 95% CI = 0.65-0.98, P = 0.028) compared with concurrent doxorubicin-docetaxel. Luminal-A disease had the best prognosis. HRs favored addition of sequential docetaxel in all subtypes, except luminal-A; but this observation was not statistically supported because of limited numbers. less thanbrgreater than less thanbrgreater thanConclusion: With further follow-up, the sequential docetaxel schedule resulted in significantly better OS than concurrent doxorubicin-docetaxel, and continued to show better DFS than sequential doxorubicin-based control.

Subject headings and genre

  • adjuvant
  • breast cancer
  • chemotherapy
  • docetaxel
  • doxorubicin
  • sequential
  • MEDICINE
  • MEDICIN

Added entries (persons, corporate bodies, meetings, titles ...)

  • Francis, P A.Peter MacCallum Cancer Centre, Australia (author)
  • Crown, JIrish Clin Oncology Research Grp, Ireland (author)
  • Quinaux, EInt Institute Drug Dev, Belgium (author)
  • Buyse, MInt Institute Drug Dev, Belgium (author)
  • De Azambuja, EUniversity of Libre Brussels, Belgium (author)
  • Margeli Vila, MHospital Badalona Germans Trias and Pujol, Spain (author)
  • Andersson, MDanish Breast Cancer Cooperat Grp, Denmark (author)
  • Nordenskjöld, BoÖstergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US(Swepub:liu)bono64 (author)
  • Jakesz, RVienna Medical Sch, Austria (author)
  • Thuerlimann, BKantonsspital, Switzerland (author)
  • Gutierrez, JClin Las Condes, Chile (author)
  • Harvey, VAuckland City Hospital, New Zealand (author)
  • Punzalan, LUniversity of Libre Brussels, Belgium (author)
  • DellOrto, PUniversity of Milan, Italy (author)
  • Larsimont, DUniversity of Libre Brussels, Belgium (author)
  • Steinberg, ISanofi Oncol, England (author)
  • Gelber, R D.IBCSG, MA USA (author)
  • Piccart-Gebhart, MUniversity of Libre Brussels, Belgium (author)
  • Viale, GUniversity of Milan, Italy (author)
  • Di Leo, AHospital Prato, Italy (author)
  • Hospital Prato, ItalyPeter MacCallum Cancer Centre, Australia (creator_code:org_t)

Related titles

  • In:Annals of Oncology: Oxford University Press (OUP): Policy A124:5, s. 1203-12110923-75341569-8041

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view